Virtu Financial LLC Takes $2.42 Million Position in IDEXX Laboratories, Inc. $IDXX

Virtu Financial LLC bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 3,584 shares of the company’s stock, valued at approximately $2,424,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Elyxium Wealth LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $3,666,459,000. J. Stern & Co. LLP boosted its stake in shares of IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after buying an additional 2,642,200 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in shares of IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after buying an additional 1,442,174 shares in the last quarter. Wellington Management Group LLP grew its position in shares of IDEXX Laboratories by 318.1% during the fourth quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after buying an additional 592,834 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $332,265,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $562.09 on Friday. The stock has a 50-day simple moving average of $561.66 and a 200-day simple moving average of $620.91. The stock has a market cap of $44.34 billion, a P/E ratio of 41.39, a P/E/G ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on IDXX shares. UBS Group reduced their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.